Gilead Sciences: The FDA Approved Yescarta® – The First CAR T-Cell Therapy for Initial Treatment of Relapsed or Refractory LBCL

Gilead Sciences' Product Yescarta
Kite - a Gilead Sciences (GILD) Company, announced the U.S. FDA has approved Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma (LBCL) refractory to first-line chemo-immunotherapy or that which relapses within 12 months of first-line chemo-immunotherapy.

Yescarta demonstrated a clinically meaningful and statistically significant . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.